Interface Biologics, Inc.
Ripple Therapeutics is a clinical stage ophthalmic therapeutics company focused on delivering sustained drug delivery without the use of polymers. Their platform utilizes prodrug technology to generate novel therapeutics that improve patient outcomes, simplify care management, and reduce costs. They have a pipeline of products and collaborations aimed at treating eye diseases such as glaucoma, retinal disorders, and others, with a focus on controlled, predictable drug release and safety.
Industries
Nr. of Employees
small (1-50)
Interface Biologics, Inc.
MaRS Center, South Tower, 101 College Street, Suite 300, Toronto, ON, M5G 1L7
Patents
Products
Intravitreal sustained-release dexamethasone implant (prodrug-based)
An implant composed solely of a prodrug material that enables sustained dexamethasone delivery to the retina for at least six months when administered by intravitreal injection; designed to reduce treatment burden in diabetic macular edema (DME) and retinal vein occlusion (RVO).
Intracameral sustained-release implant for IOP reduction (prodrug-based)
A biodegradable intracameral implant designed for sustained delivery of IOP-lowering agents with potential repeat‑dosing capability to manage open-angle glaucoma and ocular hypertension.
Intravitreal sustained-release dexamethasone implant (prodrug-based)
An implant composed solely of a prodrug material that enables sustained dexamethasone delivery to the retina for at least six months when administered by intravitreal injection; designed to reduce treatment burden in diabetic macular edema (DME) and retinal vein occlusion (RVO).
Intracameral sustained-release implant for IOP reduction (prodrug-based)
A biodegradable intracameral implant designed for sustained delivery of IOP-lowering agents with potential repeat‑dosing capability to manage open-angle glaucoma and ocular hypertension.
Services
Lead preclinical programs including nonclinical safety, tolerability and pharmacology studies to advance ocular implant candidates to clinical readiness for partner programs.
Evaluation agreements and licensing arrangements allowing external organizations to assess and license the prodrug implant platform for specific APIs and indications.
Development of scalable, low‑cost manufacturing processes for prodrug implants and coordination with CDMOs for particle engineering and scale-up beyond ophthalmology.
Execution and reporting of early‑phase clinical studies for ocular implants to generate safety, efficacy and durability data for regulatory and commercial progression.
Lead preclinical programs including nonclinical safety, tolerability and pharmacology studies to advance ocular implant candidates to clinical readiness for partner programs.
Evaluation agreements and licensing arrangements allowing external organizations to assess and license the prodrug implant platform for specific APIs and indications.
Development of scalable, low‑cost manufacturing processes for prodrug implants and coordination with CDMOs for particle engineering and scale-up beyond ophthalmology.
Execution and reporting of early‑phase clinical studies for ocular implants to generate safety, efficacy and durability data for regulatory and commercial progression.
Expertise Areas
- Ophthalmic sustained‑release drug delivery
- Prodrug chemistry and materials design
- Preclinical development and in vivo ocular studies
- Phase I/II clinical trial management and execution
Key Technologies
- Prodrug-based sustained-release materials
- Surface erosion / zero-order release kinetics
- Intravitreal and intracameral implant delivery
- Extrusion and pulled-fiber processing
News & Updates
Ripple presented findings from the RIPPLE-1 clinical trial of the IBE-814 IVT Implant at ARVO 2024, demonstrating safety, efficacy, and durability in treating DME and RVO.
Ripple presented at Eyecelerator @ ASCRS 2024 in Boston, showcasing their controlled drug delivery platform and pipeline.
Ripple announced agreements with Glaukos to develop sustained release implants for glaucoma and retinal diseases, leveraging their proprietary technology platform.
Ripple was featured in LSO’s Success Stories publication, highlighting their innovative work in Ontario’s life sciences sector.
Ripple announced agreements with Glaukos to develop sustained release implants for glaucoma and retinal diseases, leveraging their proprietary technology platform.
Ripple presented findings from the RIPPLE-1 clinical trial at ARVO 2024, demonstrating safety, efficacy, and durability in treating eye diseases.
Ripple presented findings from the RIPPLE-1 clinical trial of the IBE-814 IVT Implant at ARVO 2024, demonstrating safety, efficacy, and durability in treating DME and RVO.
Ripple presented at Eyecelerator @ ASCRS 2024 in Boston, showcasing their controlled drug delivery platform and pipeline.
Ripple announced agreements with Glaukos to develop sustained release implants for glaucoma and retinal diseases, leveraging their proprietary technology platform.
Ripple was featured in LSO’s Success Stories publication, highlighting their innovative work in Ontario’s life sciences sector.
Ripple announced agreements with Glaukos to develop sustained release implants for glaucoma and retinal diseases, leveraging their proprietary technology platform.
Ripple presented findings from the RIPPLE-1 clinical trial at ARVO 2024, demonstrating safety, efficacy, and durability in treating eye diseases.